Background: The features of oral hairy leukoplakia (OHL) have been widely reported in the literature.
short time following the diagnosis of OHL. Subsequently, OHL was included in the 1993 Revised Classification System for HIV Infection and Expanded Case Definition for AIDS among Adolescents and Adults. 2 Furthermore, the European Community (EC) Clearinghouse on oral problems related to HIV Infection and the World Health Organization (WHO) Collaborating Centre on the oral manifestations of the Human Immunodeficiency Virus 3 included OHL in its classification.
OHL has been reported to occur in all risk groups for HIV infection including homosexual men, patients with haemophilia, injecting drug users, partners of people with HIV infection and children. In rare cases, OHL has been identified in patient groups who are immunosuppressed as a result of immunosuppressive mechanisms other than HIV infection. [4] [5] Epstein-Barr virus (EBV) is accepted as the aetiologic agent for this lesion and demonstration of its presence is required for the definitive diagnosis of OHL. 3 This virus, a member of the herpes family, infects a large proportion of the world's population and is the aetiologic factor in a range of diseases including infectious mononucleosis, Burkitt's lymphoma and nasopharyngeal carcinoma. The exact role EBV plays in the pathogenesis of OHL is unclear and it is yet to be determined why OHL is predominantly found on the lateral border of the tongue.
Several studies have investigated OHL with respect to its clinical appearance, 1, [6] [7] [8] histologic features 1, 6 and relevance to HIV disease progression. [9] [10] [11] [12] [13] The role of OHL as an indicator of HIV progression in Australian populations has not been described. This analysis of OHL in a South Australian HIV-infected population was carried out in order to gain more information on the lesion in the Australian setting.
Introduction
Oral hairy leukoplakia (OHL) is a white, nonremovable lesion, usually confined to the lateral borders of the tongue. It was first reported in 1984 when it was detected in a group of HIV-infected patients in San Francisco. 1 The importance of OHL as an indicator of immunosuppression and poor prognosis of HIV disease was recognised soon after it was first described. 1 The authors observed that a proportion of the patients developed AIDS-defining illnesses within a relatively *Dental School, The University of Adelaide. †Special Needs Unit, Adelaide Dental Hospital.
principally private medical practitioners, the Royal Adelaide Hospital and the Flinders Medical Centre.
The information recorded at each patient's visit included estimated time since HIV seroconversion, date of diagnosis, CD4+ T-lymphocyte counts, current medication and any AIDS-defining illnesses they may have experienced. All this information was provided through consultation with the patients' referring medical practitioners.
For the purpose of this study, data derived from records were analysed for the prevalence and site of OHL; presence of OHL and AIDS-defining illness; presence of OHL and concurrent medication; presence of OHL and length of time since infection with HIV; and presence of OHL and CD4+ T-lymphocyte count.
OHL was defined according to the EC-Clearinghouse-WHO criteria. 3 According to these criteria, OHL is a white lesion that is present on the lateral border of the tongue. The lesions can extend on to the ventral and dorsal surfaces of the tongue and, in some cases, involve the buccal mucosa. Medical conditions were classed as AIDS-defining conditions according to the 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS among Adolescents and Adults. 2 Data were statistically analysed using chi-squared analysis.
Results
The group of 197 patients was composed of 186 (94.4 per cent) males and 11 (5.6 per cent) females. The mean age of the group was 36.9 years (range 19-67 years). One hundred and eighty-one patients were male homosexuals, 13 patients (two male, 11 female) had a known history of injecting drug use and three patients (all male) had haemophilia. Thirty-nine patients died during the period January 1986 to February 1995.
Prevalence and site of oral hairy leukoplakia
Clinical evidence of OHL was seen on the lateral border of the tongue in 89 patients (45.2 per cent). In 40 (44.9 per cent) of these cases, OHL was bilateral.
In three patients, OHL also occurred on the buccal mucosa. These three patients also had bilateral OHL lesions on their tongues.
Presence of oral hairy leukoplakia and AIDS-defining illness
One hundred and sixty-one patients had no AIDSdefining medical condition recorded in their dental records. Of these, 70 (43.5 per cent) had OHL lesions. Thirty-six patients showed an AIDS-defining illness recorded in their case notes ( Presence of oral hairy leukoplakia and length of time since infection with HIV The relationship between the presence of OHL and the length of time each patient had been infected with HIV is shown in Table 3 The patients were divided into three groups according to CD4+ T-lymphocyte count, namely <200 cells/µL, 200-500 cells/µL and >500 cells/µL. Table 4 shows the relationship between CD4+ T-lymphocyte count and the presence of OHL [X 2 =1.966, 0.1<p<0.5 ( 2 analysis)]. In patients infected with HIV for less than five years, those who had OHL had a mean CD4+ T-lymphocyte count of 303.14 cells/µL compared with 400.18 cells/µL in patients without OHL. Table 5 shows the relationship between CD4+ T-lymphocyte count and the presence of OHL in patients infected with HIV for less than five years [X 2 =0.425, p>0.5 ( 2 analysis)]. In patients who had had HIV infection for between five and 10 years, those who had OHL had a mean CD4+ T-lymphocyte count of 404.03 cells/µL compared with 385.21 cells/µL in patients without OHL. Table 6 shows the relationship between CD4+ T-lymphocyte count and the presence of OHL in patients infected with HIV for between five and 10 years [X 2 =1.122, p>0.5 ( 2 analysis)]. In patients infected with HIV for more than 10 years, those who had OHL had a mean CD4+ T-lymphocyte count of 174.85 cells/µL compared with 345.60 cells/µL in patients without OHL. Table 7 shows the relationship between CD4+ T-lymphocyte count and the presence of OHL in patients infected with HIV for more than 10 years [X 2 =3.608, 0.1<p<0.5 ( 2 analysis)].
Discussion
There are limited Australian data describing the oral manifestations of HIV infection. Coates et al 14 reported a study of the social impact of oral conditions among HIV-infected dental patients in South Australia. This study concentrated on clinical dental indices such as the number of decayed, missing and filled teeth and the community periodontal index of treatment needs. The present study provides additional, more specific, information on OHL in relation to its association with systemic features of HIV disease.
OHL attracted attention early in the global HIV epidemic because of its potential significance as a prognostic factor for HIV infection. Its presence, as suggested by Greenspan et al, 1 was thought to herald the progression to AIDS or even death. Other international studies have since found OHL to be a marker of immunosuppression and progression of HIV disease. [9] [10] [11] [12] 15 The diagnosis of OHL in this study was based on presumptive criteria as outlined by the 1993 ECClearinghouse-WHO criteria. 3 These diagnostic criteria require the lesions are white and present on the lateral border of the tongue. The lesions can extend on to the ventral and dorsal surfaces of the tongue and, in some cases, involve the buccal mucosa. Definitive diagnosis of OHL requires the demonstration of EBV within the lesions, or, where this is not possible, a lack of response to antifungal treatment can add weight to a presumptive diagnosis. It was not always evident, by examination of the case note entries, whether antifungal treatment was employed to differentiate lesions.
In the present study, the clinical findings in relation to the predominant site of occurrence of OHL were in accord with those of investigators from other countries. Schiødt et al 6 found, in a sample of 50 patients, OHL occurred exclusively on the lateral border of the tongue and 86 per cent of patients had OHL occurring bilaterally. In the present study, bilateral OHL was not observed as frequently as this and only 44.9 per cent of our patients showed OHL occurring bilaterally on their tongues.
There are two explanations for this difference. First, there may have been inaccuracies in the diagnosis of OHL in both the present study and in the study by Schiødt et al. Second, the presence of OHL in patient records could have been under-reported. Apart from the possibility of a real difference in the clinical presentation of OHL between the two studies, the differences may be a reflection of the difference in sample sizes. The present study may give a more accurate picture of the clinical presentation of OHL because of the greater number of subjects in the study.
Other studies have observed more extensive involvement of the oral cavity by OHL, [7] [8] and have described OHL occurring on the buccal mucosa, floor of the mouth, palate and dorsal surface of the tongue. OHL was found on the buccal mucosa in three patients in the present study. Although an interesting clinical feature from a diagnostic point of view, it has been shown the severity of OHL, as opposed to its presence, does not seem to be predictive for immunosuppression or for the development of AIDS in patients infected with HIV. 6 The most common oral manifestations of HIV infection, OHL and oral candidiasis, have been found to occur sooner after HIV seroconversion than the development of AIDS. Lifson et al 13 found, within five years after seroconversion, 42 per cent of the patients in their study developed OHL. Although not statistically significant, the present study found a slight increase in the prevalence of OHL after a period of infection with HIV that was greater than or equal to 10 years; in this instance, OHL was found in 55.6 per cent of patients.
Extensive OHL has been reported in two studies where it occurred concurrently with an AIDS-defining illness. Kabani et al 7 described extensive OHL in a patient four months after the patient developed KS and PCP. Southam et al 16 reported a case where OHL occurred in the epithelium overlying KS lesions in the oral cavity.
The present study examined current or previous AIDS-defining illnesses relative to the prevalence of OHL. Only 36 out of the 197 patients were identified as having had an illness that was AIDS defining. In this group of patients, the prevalence of OHL was 52.8 per cent. The prevalence of OHL in the 161 patients without any reported AIDS-defining condition was 43.5 per cent. There was no statistical significance in the prevalence of OHL between these two groups.
In relation to a single AIDS-defining illness, because of the low patient numbers, it was not possible to draw any conclusions regarding the relationship to OHL.
One hundred and fifty-eight patients in this study were taking medication of some kind, either for the treatment of HIV infection, the treatment of opportunistic infections, or for the prophylaxis of opportunistic infections. The prevalence of OHL in patients who were taking medication was 48.7 per cent. Although this figure is only slightly higher than the overall prevalence of 45.2 per cent for the sample as a whole, it may be a reflection of more advanced immune deficiency in some of these patients.
Some studies have reported a resolution of OHL following the commencement of antiviral medication. [17] [18] [19] Forty-nine patients in the present study were taking aciclovir and the prevalence of OHL in this group was 28.1 per cent, statistically significant compared with the prevalence of OHL in patients who were not taking aciclovir. Given the postulated role of EBV in the pathogenesis of OHL, it follows that aciclovir should have some impact on the prevalence of the lesion. This drug has been shown to stop EBV production by inhibiting the EBV DNA polymerase enzyme. 21 Resnick et al 18 described the regression of OHL following the use of aciclovir in five out of six patients who had clinical and histological evidence of OHL. The use of intravenous aciclovir as a potential treatment for OHL has also been reported, resulting in resolution of OHL until cessation of the treatment. 20 Although the response of OHL to various drugs is interesting as far as the behaviour of the lesion is concerned, treatment of OHL is not generally required because of the asymptomatic nature of the lesion. Antiretroviral drugs have also been reported to result in resolution of OHL. Phelan and Klein 19 presented a case report of a patient who had a 10-month history of continuous OHL. Within six weeks of treatment with AZT for HIV infection, the OHL had completely resolved. Ninety-one patients in the present study were taking AZT and again the prevalence of OHL was significantly reduced compared with the overall prevalence in the total sample population.
The reduced prevalence of OHL in patients taking antiviral medication may be a result of direct action by the drug. This is especially likely in the case of aciclovir and ganciclovir, which are drugs directed at herpes viruses (EBV is a member of the herpes virus family). Alternatively, the patient's immune function may be improved by antiviral medication, enabling a more effective immune response to EBV, thus reducing viral replication. Although these drugs definitely have a beneficial effect on OHL lesions, the results of the present study indicate there must be other factors that lead to the development of OHL. Hence, it appears likely the pathogenesis of OHL is multifactorial and that viruses, namely EBV, are possibly co-factors in the development of OHL.
Thirty-nine patients were not taking any medication and the prevalence of OHL in this group was 30.8 per cent. The lower prevalence of OHL than that found in the group of patients taking medication may reflect the fact the patients not on medication were healthier in terms of their immune function.
OHL was not associated with a lower CD4+ Tlymphocyte count in this Australian group of patients. Further detailed longitudinal studies would provide more accurate information and it would also be interesting to observe how the presence of OHL relates to HIV viral load.
CD4+T-lymphocyte counts have been used to monitor the health of patients with HIV infection to give an indication of HIV disease progression. CD4+ Tlymphocyte counts also help predict the development of opportunistic infections. [22] [23] Reichart et al 24 found, in a study of 95 HIV-infected patients with clinical and histological evidence of OHL, the average CD4+ Tlymphocyte count was 149 cells/µL (range 10-470 cells/µL). Glick et al 25 found, in patients with OHL, the mean CD4+ T-lymphocyte count was 143.3 cells/µL. The same study reported the presence of OHL in HIVpositive patients had a positive predictive value of 70.1 per cent and the CD4+ T-lymphocyte count would be less than 200 cells/µL. In addition, Begg et al 11 found a significant association between a low level of CD4+ Tlymphocytes and OHL in injecting drug users.
A chronological model of HIV disease progression has been illustrated by Stewart 22 in which CD4+ Tlymphocyte counts and opportunistic infections associated with HIV are correlated. According to this model, oral manifestations of HIV infection are more likely to occur at an intermediate level of immunodeficiency where CD4+ T-lymphocytes are between 200-500 cells/µL.
In the present study, it was interesting to note the range of CD4+ T-lymphocyte counts was broad, both in the group of patients without OHL (0-2200 cells/µL) and in the group of patients with OHL (0-1200 cells/µL). This was also reported by Lifson et al. 13 The mean CD4+ T-lymphocyte count for patients with OHL in the present study was 294 cells/µL, which is in accordance with the model proposed by Stewart. 22 The mean CD4+ T-lymphocyte count in patients without OHL was 377 cells/µL. Ravina et al 26 found patients with OHL demonstrated a greater decline in CD4+ T-lymphocytes over an eightyear period compared with HIV-infected patients without OHL. This is also inferred by the results of the present study by determining CD4+ T-lymphocyte counts and presence of OHL after placing the patients into groups according to the length of time since estimated seroconversion.
At less than five years since estimated seroconversion, the CD4+ T-lymphocyte count for patients with OHL was 303 cells/µL compared with 400 cells/µL in patients without OHL. When the time since estimated seroconversion was greater than 10 years, the CD4+ Tlymphocyte counts in patients with OHL was 175 cells/µL compared with 346 cells/µL in patients without OHL. An exception noted in the current study was a reversal of the CD4+ T-lymphocyte count in the group of patients who had seroconverted between five and 10 years previously. In this group of patients, CD4+ T-lymphocyte counts were higher in patients with OHL (404 cells/µL) than in patients without OHL (385cells/µL).
The results of this study do not demonstrate any statistically significant relationship between the presence of OHL and CD4+ T-lymphocyte count. This supports our original hypothesis that the presence of
